EQRx, Inc. - Common Stock (NQ: EQRX )
1.830 +0.010 (+0.55%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
All News about EQRx, Inc. - Common Stock
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....
Via Talk Markets
Earnings Outlook For EQRx
May 05, 2023
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion
November 12, 2022
Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each...
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
December 14, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022
November 11, 2022
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
November 10, 2022
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's...
EQRx to Participate in the Jefferies 2022 London Healthcare Conference
November 07, 2022
Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of...
Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session
October 19, 2022
Gainers SenesTech, Inc. (NASDAQ: SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following